
The Union Health Ministry on 3 November proposed amending the Drugs Rules, 1945, to require every drug manufacturer to formally appoint a qualified person to authorise the release of each batch into the market. Companies will also have to issue a Batch Release Certificate in a prescribed format and keep records for each lot. The ministry said the move fills a gap: while manufacturers must declare technical staff for manufacturing and testing, rules did not specifically require naming who approves a batch for sale.

The proposal comes amid quality concerns in India’s $60-billion pharmaceutical industry, Livemint reported, including contaminated cough syrups linked to child deaths in Gambia, Uzbekistan and Madhya Pradesh and Rajasthan in 2025. The ministry said the requirement will strengthen compliance with Good Manufacturing Practices and reinforce drug quality assurance. Stakeholders have 30 days from the draft notification’s publication to submit objections and suggestions.
All three outlets report the same health ministry proposal with near-identical facts: the draft amendment to Rule 68 of the Drugs Rules, 1945, will require drug manufacturers to designate a qualified person for batch release, issue a Batch Release Certificate and maintain records. Livemint adds the wider context, noting the move follows contaminated cough syrup deaths in Gambia, Uzbekistan and Madhya Pradesh and Rajasthan in 2025, and also reports that Mint first covered the plan in February 2025. Yespunjab sticks to the ministry's stated rationale, mentioning no prior deaths. Business Standard specifies the designated person must be a graduate in pharmacy, pharmaceutical chemistry, medicine with clinical pharmacology or microbiology, and notes that till now licences were approved by the CLAA. The differences are in scope: Livemint gives market size and crisis backdrop, while the other two stay inside the draft text. Stakeholders have 30 days to submit feedback.
Coverage: 3 sources, 3 neutral
Sources (3): yespunjab.com (neutral report), livemint.com (neutral report), business-standard.com (neutral report)
This brief was synthesised by AI from the 3 sources linked above, so one read covers every framing they carry. Methodology and corrections.